/ /

  • linkedin
  • Increase Font
  • Sharebar

    Multiple next-generation stents lead to better IOP control

    Patients with mild-to-moderate, open-angle glaucoma had IOP reduction of 20% or more



    By month 12, 100% of patients had a 20% or greater decrease in their preoperative unmedicated IOP, Dr. Lindstrom said.

    Seventy-five percent had a 20% or greater decrease compared with preoperative medicated IOP. Without medication, 100% had an IOP of 18 mm Hg or lower, and 67% had an IOP of 15 mm Hg or lower.

    An analysis of the mean IOP through month 18 reveals the IOP-lowering trends, Dr. Lindstrom said.

    Although the mean IOP increased to 24.4 mm Hg right after the washout period—when patients stopped using their medications—it dropped down to 14.3 mm Hg at month 1 and then ended at 14.4 mm Hg at month 18.

    “That was a 41% decrease from the preoperative unmedicated IOP,” Dr. Lindstrom said.

    There were no major safety issues in the study; one patient had a loss of BCVA because of a cataract progression. At month 18, 93% of patients had BCVA of 20/40 or better.

    The study did have some limitations, Dr. Lindstrom said.It was open label, there was no control group, and all patients were white.

    Additionally, the qualifying IOP was not measured on multiple days. However, the study showed overall good outcomes and safety, Dr. Lindstrom said.

    He added that although the second-generation device is not yet available in the United States, it should be eventually approved and used here.


    Richard L. Lindstrom, MD

    E: [email protected]

    This article was adapted from Dr. Lindstrom’s presentation at the 2016 meeting of the American Society of Cataract and Refractive Surgery. Dr. Lindstrom is a consultant for and equity owner in Glaukos.





    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results